| 저자(한글) |
Fatiguso, G.,Allegra, S.,Calcagno, A.,Baietto, L.,Motta, I.,Favata, F.,Cusato, J.,Bonora, S.,Perri, G.D.,D'Avolio, A. |
| 저자(영문) |
|
| 소속기관 |
|
| 소속기관(영문) |
|
| 출판인 |
|
| 간행물 번호 |
|
| 발행연도 |
2016-01-01 |
| 초록 |
We evaluated ethambutol plasma and intracellular pharmacokinetic according to single nucleotide polymorphisms in ABCB1, OATP1B1, PXR, VDR, CYP24A1 and CYP27B1 genes. Mycobacterium tubercolosis infected patients were enrolled. Standard weight-adjusted antitubercular treatment was administered intravenously for 2 weeks and then orally. Allelic discrimination was performed by real-time PCR. Ethambutol plasma and intracellular concentrations were measured by UPLC-MS/MS methods. Twenty-four patients were included. Considering weeks 2 and 4, median plasma C trough were 73ng/mL and 247ng/mL, intracellular C trough were 16,863ng/mL and 13,535ng/mL, plasma C max were 5627ng/mL and 2229ng/mL, intracellular C max were 133,830ng/mL and 78,544ng/mL. At week 2, ABCB1 3435 CT/TT (p=0.023) and CYP24A1 8620 AG/GG (p=0.030) genotypes for plasma C trough , BsmI AA (p=0.036) for intracellular C trough and BsmI AA (p max , remained in linear regression analysis as predictive factors. Concerning week 4 only ABCB1 3435 CT/TT (p=0.035) and Cdx2 AG/GG (p=0.004) genotypes for plasma C trough and BsmI AA (p=0.028) for plasma C max were retained in final regression model. We reveal, for the first time, the possible role of single nucleotide polymorphisms on ethambutol plasma and intracellular concentrations; this may further the potential use of pharmacogenetic for tailoring antitubercular treatment. |
| 원문URL |
http://click.ndsl.kr/servlet/OpenAPIDetailView?keyValue=03553784&target=NART&cn=NART74657889 |
| 첨부파일 |
|
